61 related articles for article (PubMed ID: 1456889)
1. Mapping the immune response to the outer domain of a human immunodeficiency virus-1 clade C gp120.
Chen H; Xu X; Lin HH; Chen SH; Forsman A; Aasa-Chapman M; Jones IM
J Gen Virol; 2008 Oct; 89(Pt 10):2597-2604. PubMed ID: 18796729
[TBL] [Abstract][Full Text] [Related]
2. Sequential immunization with V3 peptides from primary human immunodeficiency virus type 1 produces cross-neutralizing antibodies against primary isolates with a matching narrow-neutralization sequence motif.
Eda Y; Takizawa M; Murakami T; Maeda H; Kimachi K; Yonemura H; Koyanagi S; Shiosaki K; Higuchi H; Makizumi K; Nakashima T; Osatomi K; Tokiyoshi S; Matsushita S; Yamamoto N; Honda M
J Virol; 2006 Jun; 80(11):5552-62. PubMed ID: 16699036
[TBL] [Abstract][Full Text] [Related]
3. The c3-v4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection.
Moore PL; Gray ES; Choge IA; Ranchobe N; Mlisana K; Abdool Karim SS; Williamson C; Morris L;
J Virol; 2008 Feb; 82(4):1860-9. PubMed ID: 18057243
[TBL] [Abstract][Full Text] [Related]
4. Anti-V3 humanized antibody KD-247 effectively suppresses ex vivo generation of human immunodeficiency virus type 1 and affords sterile protection of monkeys against a heterologous simian/human immunodeficiency virus infection.
Eda Y; Murakami T; Ami Y; Nakasone T; Takizawa M; Someya K; Kaizu M; Izumi Y; Yoshino N; Matsushita S; Higuchi H; Matsui H; Shinohara K; Takeuchi H; Koyanagi Y; Yamamoto N; Honda M
J Virol; 2006 Jun; 80(11):5563-70. PubMed ID: 16699037
[TBL] [Abstract][Full Text] [Related]
5. Immunotyping of human immunodeficiency virus type 1 (HIV): an approach to immunologic classification of HIV.
Zolla-Pazner S; Gorny MK; Nyambi PN; VanCott TC; Nádas A
J Virol; 1999 May; 73(5):4042-51. PubMed ID: 10196300
[TBL] [Abstract][Full Text] [Related]
6. An investigation of the high-avidity antibody response to glycoprotein 120 of human immunodeficiency virus type 1.
Binley JM; Arshad H; Fouts TR; Moore JP
AIDS Res Hum Retroviruses; 1997 Aug; 13(12):1007-15. PubMed ID: 9264287
[TBL] [Abstract][Full Text] [Related]
7. Mapping the protein surface of human immunodeficiency virus type 1 gp120 using human monoclonal antibodies from phage display libraries.
Ditzel HJ; Parren PW; Binley JM; Sodroski J; Moore JP; Barbas CF; Burton DR
J Mol Biol; 1997 Apr; 267(3):684-95. PubMed ID: 9126846
[TBL] [Abstract][Full Text] [Related]
8. AIDS/HIV. Host controls of HIV neutralizing antibodies.
Haynes BF; Verkoczy L
Science; 2014 May; 344(6184):588-9. PubMed ID: 24812389
[TBL] [Abstract][Full Text] [Related]
9. Structure determination of an anti-HIV-1 Fab 447-52D-peptide complex from an epitaxially twinned data set.
Dhillon AK; Stanfield RL; Gorny MK; Williams C; Zolla-Pazner S; Wilson IA
Acta Crystallogr D Biol Crystallogr; 2008 Jul; D64(Pt 7):792-802. PubMed ID: 18566514
[TBL] [Abstract][Full Text] [Related]
10. Preclinical Development of a Fusion Peptide Conjugate as an HIV Vaccine Immunogen.
Ou L; Kong WP; Chuang GY; Ghosh M; Gulla K; O'Dell S; Varriale J; Barefoot N; Changela A; Chao CW; Cheng C; Druz A; Kong R; McKee K; Rawi R; Sarfo EK; Schön A; Shaddeau A; Tsybovsky Y; Verardi R; Wang S; Wanninger TG; Xu K; Yang GJ; Zhang B; Zhang Y; Zhou T; ; Arnold FJ; Doria-Rose NA; Lei QP; Ryan ET; Vann WF; Mascola JR; Kwong PD
Sci Rep; 2020 Feb; 10(1):3032. PubMed ID: 32080235
[TBL] [Abstract][Full Text] [Related]
11. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
[TBL] [Abstract][Full Text] [Related]
12. V3: HIV's switch-hitter.
Hartley O; Klasse PJ; Sattentau QJ; Moore JP
AIDS Res Hum Retroviruses; 2005 Feb; 21(2):171-89. PubMed ID: 15725757
[TBL] [Abstract][Full Text] [Related]
13. The quest for an AIDS vaccine: the state of the art and current challenges.
Kurth R; Binninger D; Ennen J; Denner J; Hartung S; Norley S
AIDS Res Hum Retroviruses; 1991 May; 7(5):425-33. PubMed ID: 1873078
[TBL] [Abstract][Full Text] [Related]
14. Immunological reactivity of a human immunodeficiency virus type I derived peptide representing a consensus sequence of the GP120 major neutralizing region V3.
Wagner R; Modrow S; Böltz T; Fliessbach H; Niedrig M; von Brunn A; Wolf H
Arch Virol; 1992; 127(1-4):139-52. PubMed ID: 1456889
[TBL] [Abstract][Full Text] [Related]
15. Variant-specific monoclonal and group-specific polyclonal human immunodeficiency virus type 1 neutralizing antibodies raised with synthetic peptides from the gp120 third variable domain.
Laman JD; Schellekens MM; Abacioglu YH; Lewis GK; Tersmette M; Fouchier RA; Langedijk JP; Claassen E; Boersma WJ
J Virol; 1992 Mar; 66(3):1823-31. PubMed ID: 1637373
[TBL] [Abstract][Full Text] [Related]
16. Single peptide and anti-idiotype based immunizations can broaden the antibody response against the variable V3 domain of HIV-1 in mice.
Boudet F; Keller H; Kieny MP; Thèze J
Mol Immunol; 1995 May; 32(7):449-57. PubMed ID: 7783749
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
